Design of growth factor antagonists with antiangiogenic and antitumor properties

Saïd M. Sebti, Andrew Hamilton

Research output: Contribution to journalArticle

Abstract

This review describes our recent efforts in the development of novel therapies for cancer. Our primary approach is to design synthetic agents that antagonize the function of growth factors that are critically involved in oncogenesis and angiogenesis. We achieve this by designing synthetic molecules that can recognize the exterior surface of the growth factor and so block the interaction with its receptor tyrosine kinase. A key step is the construction of synthetic agents that contain a large (>400Å2) and functionalized surface area to recognize a complementary surface on the target growth factor. In the course of this work we have discovered a molecule, GFB-111, that binds to PDGF, prevents it from binding to its receptor tyrosine kinase, blocks PDGF-induced receptor autophosphorylation, activation of Erk1 and Erk2 kinases and DNA synthesis. The binding affinity for PDGF is high (IC50 = 250 nM) and selective over EGF, IGF-1, aFGF, bFGF and HRGβ. In nude mouse models GFB-111 also shows significant inhibition of tumor growth and angiogenesis.

Original languageEnglish (US)
Pages (from-to)6566-6573
Number of pages8
JournalOncogene
Volume19
Issue number56
DOIs
StatePublished - Dec 27 2000

Fingerprint

Intercellular Signaling Peptides and Proteins
Receptor Protein-Tyrosine Kinases
Polynucleotide 5'-Hydroxyl-Kinase
Platelet-Derived Growth Factor Receptors
Insulin-Like Growth Factor I
Epidermal Growth Factor
Nude Mice
Inhibitory Concentration 50
Neoplasms
Carcinogenesis
Growth
GFB 111
Therapeutics
histidine-rich proteins

Keywords

  • Angiogenesis
  • Cancer drug discovery
  • Oncogenesis
  • Platelet-derived growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Design of growth factor antagonists with antiangiogenic and antitumor properties. / Sebti, Saïd M.; Hamilton, Andrew.

In: Oncogene, Vol. 19, No. 56, 27.12.2000, p. 6566-6573.

Research output: Contribution to journalArticle

@article{351395a075cb436bac502a0962c02e66,
title = "Design of growth factor antagonists with antiangiogenic and antitumor properties",
abstract = "This review describes our recent efforts in the development of novel therapies for cancer. Our primary approach is to design synthetic agents that antagonize the function of growth factors that are critically involved in oncogenesis and angiogenesis. We achieve this by designing synthetic molecules that can recognize the exterior surface of the growth factor and so block the interaction with its receptor tyrosine kinase. A key step is the construction of synthetic agents that contain a large (>400{\AA}2) and functionalized surface area to recognize a complementary surface on the target growth factor. In the course of this work we have discovered a molecule, GFB-111, that binds to PDGF, prevents it from binding to its receptor tyrosine kinase, blocks PDGF-induced receptor autophosphorylation, activation of Erk1 and Erk2 kinases and DNA synthesis. The binding affinity for PDGF is high (IC50 = 250 nM) and selective over EGF, IGF-1, aFGF, bFGF and HRGβ. In nude mouse models GFB-111 also shows significant inhibition of tumor growth and angiogenesis.",
keywords = "Angiogenesis, Cancer drug discovery, Oncogenesis, Platelet-derived growth factor",
author = "Sebti, {Sa{\"i}d M.} and Andrew Hamilton",
year = "2000",
month = "12",
day = "27",
doi = "10.1038/sj.onc.1204121",
language = "English (US)",
volume = "19",
pages = "6566--6573",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "56",

}

TY - JOUR

T1 - Design of growth factor antagonists with antiangiogenic and antitumor properties

AU - Sebti, Saïd M.

AU - Hamilton, Andrew

PY - 2000/12/27

Y1 - 2000/12/27

N2 - This review describes our recent efforts in the development of novel therapies for cancer. Our primary approach is to design synthetic agents that antagonize the function of growth factors that are critically involved in oncogenesis and angiogenesis. We achieve this by designing synthetic molecules that can recognize the exterior surface of the growth factor and so block the interaction with its receptor tyrosine kinase. A key step is the construction of synthetic agents that contain a large (>400Å2) and functionalized surface area to recognize a complementary surface on the target growth factor. In the course of this work we have discovered a molecule, GFB-111, that binds to PDGF, prevents it from binding to its receptor tyrosine kinase, blocks PDGF-induced receptor autophosphorylation, activation of Erk1 and Erk2 kinases and DNA synthesis. The binding affinity for PDGF is high (IC50 = 250 nM) and selective over EGF, IGF-1, aFGF, bFGF and HRGβ. In nude mouse models GFB-111 also shows significant inhibition of tumor growth and angiogenesis.

AB - This review describes our recent efforts in the development of novel therapies for cancer. Our primary approach is to design synthetic agents that antagonize the function of growth factors that are critically involved in oncogenesis and angiogenesis. We achieve this by designing synthetic molecules that can recognize the exterior surface of the growth factor and so block the interaction with its receptor tyrosine kinase. A key step is the construction of synthetic agents that contain a large (>400Å2) and functionalized surface area to recognize a complementary surface on the target growth factor. In the course of this work we have discovered a molecule, GFB-111, that binds to PDGF, prevents it from binding to its receptor tyrosine kinase, blocks PDGF-induced receptor autophosphorylation, activation of Erk1 and Erk2 kinases and DNA synthesis. The binding affinity for PDGF is high (IC50 = 250 nM) and selective over EGF, IGF-1, aFGF, bFGF and HRGβ. In nude mouse models GFB-111 also shows significant inhibition of tumor growth and angiogenesis.

KW - Angiogenesis

KW - Cancer drug discovery

KW - Oncogenesis

KW - Platelet-derived growth factor

UR - http://www.scopus.com/inward/record.url?scp=0034722887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034722887&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1204121

DO - 10.1038/sj.onc.1204121

M3 - Article

C2 - 11426641

AN - SCOPUS:0034722887

VL - 19

SP - 6566

EP - 6573

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 56

ER -